share_log

Quanterix To Report First Quarter 2024 Financial Results

Quanterix To Report First Quarter 2024 Financial Results

Quanterix將公佈2024年第一季度財務業績
Quanterix ·  04/29 12:00

BILLERICA, Mass.--(BUSINESS WIRE)--Apr. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T., to discuss its first quarter 2024 financial results.

馬薩諸塞州比勒裏卡--(美國商業資訊)--2024年4月29日-- Quanterix 公司 納斯達克股票代碼:QTRX)是一家通過超靈敏生物標誌物檢測推動科學發現的公司,今天宣佈,它將在美國東部時間2024年5月8日星期三上午 8:30 舉行電話會議,討論其2024年第一季度的財務業績。

Quanterix will issue a press release regarding the first quarter 2024 earnings prior to the conference call on Tuesday, May 7, 2024 after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/.

Quanterix將在2024年5月7日星期二收盤後的電話會議之前發佈有關2024年第一季度收益的新聞稿。新聞稿將發佈在Quanterix網站上,網址爲 https://www.quanterix.com/

To pre-register for the conference call with a webcast link click here and for an audio only link click here to obtain your dial-in number and passcode. Interested investors can also access the live webcast from the News & Events page within the Investors section of the Quanterix website at http://www.quanterix.com. An archived webcast replay will be available on the Company's website for one year.

使用網絡直播鏈接預註冊電話會議 點擊這裏 並用於僅限音頻的鏈接 點擊這裏 獲取您的撥入號碼和密碼。感興趣的投資者還可以從以下網址觀看網絡直播 新聞與活動 Quanterix 網站 “投資者” 部分中的頁面,網址爲 http://www.quanterix.com。存檔的網絡直播重播將在公司網站上提供,爲期一年。

About Quanterix

關於 Quanterix

From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

從發現到診斷,Quanterix的超靈敏生物標誌物檢測正在推動突破,只有通過其無與倫比的靈敏度和靈活性才能實現。該公司的Simoa 該技術爲早期血液、血清或血漿中的生物標誌物檢測提供了黃金標準,它能夠量化遠低於傳統類似方法的定量極限(LoQ)的蛋白質。其行業領先的精密儀器、數字免疫分析技術和經CLIA認證的Accelerator實驗室爲促進神經病學、腫瘤學、免疫學、心臟病學和傳染病領域的疾病理解和管理的研究提供了支持。近二十年來,Quanterix 一直是科學界值得信賴的合作伙伴,推動了在 2,900 多份同行評審期刊上發表的研究。要了解有關這家總部位於馬薩諸塞州比爾裏卡的公司的更多信息,請訪問 https://www.quanterix.com 或者在推特和領英上關注我們。

Forward-Looking Statements

前瞻性陳述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

本新聞稿包含1995年《私人證券訴訟改革法》所指的前瞻性陳述。諸如 “可能”、“將”、“期望”、“計劃”、“預期”、“估計”、“打算” 等詞語和類似表達(以及其他提及未來事件、條件或情況的詞語或表達)旨在識別前瞻性陳述。本新聞稿中的前瞻性陳述基於Quanterix截至本新聞稿發佈之日的預期和假設。這些前瞻性陳述都涉及風險和不確定性。Quanterix向美國證券交易委員會提交的文件中討論了可能導致Quanterix實際業績與本新聞稿中前瞻性陳述中表達或暗示的業績不同的因素,包括其中包含的 “風險因素” 部分。除非法律要求,否則即使有新的信息,Quanterix也沒有義務更新此處包含的任何前瞻性陳述以反映預期的任何變化。

Media:
PAN Communications
Maya Nimnicht
(510) 334-6273
quanterix@pancomm.com

媒體:
PAN 通訊
Maya Nimnicht
(510) 334-6273
quanterix@pancomm.com

Investor Relations:
Francis Pruell, Quanterix
(508) 789-1725
ir@quanterix.com

投資者關係:
弗朗西斯·普魯爾,Quanterix
(508) 789-1725
ir@quanterix.com

Source: Quanterix Corporation

來源:Quanterix 公司

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論